Breaking Finance News

A report released today by Cantor Fitzgerald about Dynavax Technologies (NDAQ:DVAX) raises the target price to $24.00

Yesterday Dynavax Technologies (NDAQ:DVAX) traded 0.00% even at $20.60. The company’s 50-day moving average is $17.04 and its 200-day moving average is $9.40. The last stock close price is up 119.12% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 1,339,253 shares of the stock were exchanged, down from an average trading volume of 2,870,920

Dynavax Technologies (NDAQ:DVAX) had its target price raised to $24.00 by Cantor Fitzgerald in a report released 9/15/2017. The new target price indicates a possible upside of 0.17% based on the company's last stock close price.

See Chart Below

Dynavax Technologies (NDAQ:DVAX)

Dynavax Technologies has a 52 week low of $3.20 and a 52 week high of $21.85 The company’s market cap is currently $0.

In addition to Cantor Fitzgerald reporting its target price, a total of 4 firms have reported on the stock. The consensus target price is $43.75 with 1 firm rating the stock a strong buy, 3 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Dynavax Technologies (NDAQ:DVAX)

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *